S. 2564 · 109th Congress
Biodefense and Pandemic Vaccine and Drug Development Act of 2006
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 109th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
BurrSponsor5 cosponsors · 5 R
5 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Biodefense and Pandemic Vaccine and Drug Development Act of 2006 - Amends the Public Health Service Act to require the Secretary of Health and Human Services to develop and make public a strategic plan to integrate biodefense and emerging infectious disease requirements with the advanced research and development, strategic initiatives for innovation, and…
What it does: CRS summary · Introduced in Senate · Apr 6, 2006
Biodefense and Pandemic Vaccine and Drug Development Act of 2006 - Amends the Public Health Service Act to require the Secretary of Health and Human Services to develop and make public a strategic plan to integrate biodefense and emerging infectious disease requirements with the advanced research and development, strategic initiatives for innovation, and the procurement of qualified countermeasures and qualified pandemic or epidemic products.
Establishes the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services (HHS).
Requires the Secretary to: (1) coordinate and oversee the acceleration of countermeasure and product advanced research and development; and (2) delegate to the Director of BARDA any necessary functions and authorities.
Establishes the Biodefense Medical Countermeasure Development Fund.
Requires the Secretary to establish the National Biodefense Science Board to provide expert advice and guidance to the Secretary on matters relating to current and future chemical, biological, nuclear, and radiological agents.
Amends the Federal Food, Drug, and Cosmetic Act to extend the period of market exclusivity from seven years to ten years for certain new drugs, antibiotics, or anti-infective drugs to treat a rare disease or condition caused by a biological agent, toxin, chemical, radiological, or nuclear agent that is deemed by the Secretary to be a material threat to the United States.
Provides an antitrust exemption for: (1) meetings and consultations held by the Secretary among persons engaged in the development of countermeasures or pandemic or epidemic products; and (2) agreements resulting from such meetings.
Prohibits payment on a security countermeasure procurement contract until the delivery of an acceptable portion of such product to the Secretary unless advance payment is necessary to ensure the success of the project.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Biodefense and Pandemic Vaccine and Drug Development Act of 2006
Latest action (Apr 6, 2006): Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S3222-3227)
Policy area: Health · Origin: Senate · Introduced: Apr 6, 2006
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.